Open AccessMultisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy
Author(s) -
Zoilo Morel,
Raúl Gabriel Pérez Suárez,
E Avalos,
S. Herrero Velázquez,
Florencia Martinez,
Verónica Lezcano,
Norma Astigarraga,
Caroline Lorenzoni Almeida Ghezzi,
Silvia Brizuela,
Gloría Samudio
Publication year - 2022
Publication title -
reumatismo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.294
H-Index - 25
eISSN - 2240-2683
pISSN - 0048-7449
DOI - 10.4081/reumatismo.2021.1448
Subject(s) - medicine , latent tuberculosis , tocilizumab , tuberculosis , immunology , bone marrow , disease , immune reconstitution inflammatory syndrome , mycobacterium tuberculosis , pediatrics , pathology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C) is a new acute-onset systemic inflammatory disease, which mainly affects children. Latent tuberculosis infection (LTBI) is characterized by the presence of immune sensitization to Mycobacterium tuberculosis (MTB) in the absence of any clinical or radiological evidence of active disease. We present a child with MIS-C related to COVID-19, with latent TB in the bone marrow, and satisfactory response to tocilizumab. It is important to pay attention in the investigation of TB cases in countries with a high prevalence of tuberculosis, especially when opting for immunusuppression.